FFRangio System vs Autoplaque

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

FFRangio System

by CathWorks (acquired by Medtronic)

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

AI Verdict

These tools are adjacent rather than direct competitors, as they serve different stages of coronary artery disease management. The FFRangio System focuses on real-time functional assessment during interventional procedures to optimize PCI decisions, while Autoplaque provides quantitative analysis of coronary plaques and stenoses from CT angiography for risk prediction and initial treatment guidance.

Choose FFRangio System if…

Choose the FFRangio System if you require real-time, wire-free physiological guidance directly within the cath lab to optimize and confirm PCI decisions. This tool is ideal for interventional cardiologists seeking immediate, drug-free FFR measurements and advanced insights during a procedure to assess lesion impact and guide stent placement.

View FFRangio System →

Choose Autoplaque if…

Choose Autoplaque if your primary need is a comprehensive, AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This software is best suited for clinicians focused on pre-procedural risk stratification, heart attack prediction, and detailed treatment planning based on non-invasive imaging data.

View Autoplaque →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	FFRangio System	Autoplaque
Pricing	Contact vendor for pricing information.	Unknown
Deployment	SaaS, on-prem, hybrid	Workstation-based post-processing application, runs on Windows or Mac OS.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	FFRangio System	Autoplaque
Name	FFRangio System	Autoplaque
Company	CathWorks	Cedars-Sinai Medical Center: AIM
Description	The CathWorks FFRangio System delivers wire-free and drug-free 3D FFR guidance, providing accurate multi-vessel FFR results and advanced insights to quickly optimize and confirm PCI decisions for patients with coronary artery disease.	Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.
Key Functionality	Real-time FFRangio values, simulated pullback curve, lesion impact assessment, integrated sizing tool, eliminates invasive pressure wires/drugs.	AI-powered quantitative analysis of atherosclerotic plaque, detection and characterization of coronary artery plaque, measurement of luminal stenoses, automated vessel/plaque/lumen segmentation.

Videos

Demos, reviews, and walkthroughs featuring FFRangio System and Autoplaque.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of the FFRangio System and Autoplaque?

The FFRangio System provides wire-free and drug-free 3D FFR guidance to optimize and confirm PCI decisions for patients with coronary artery disease. Autoplaque offers AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.

What imaging modalities do these tools utilize for their analysis?

The FFRangio System integrates with cath lab equipment and C-arm angiography systems to analyze routine angiogram images. Autoplaque analyzes coronary plaques and luminal stenoses from CT angiography images.

What specific quantitative insights or measurements does each tool provide?

The FFRangio System delivers real-time FFRangio values at every point on the coronary tree, simulated pullback curves, a Lesion Impact feature to assess residual ischemia, and an integrated sizing tool for non-invasive lesion measurements. Autoplaque provides AI-powered quantitative analysis of atherosclerotic plaque, detection and characterization of coronary artery plaque, and measurement of luminal stenoses, vessel diameter, and area.

How does each tool impact the invasiveness of coronary artery disease assessment?

The FFRangio System eliminates the need for invasive pressure wires, drugs, or a guide catheter for FFR assessment, making it a wire-free and drug-free solution. Autoplaque is a non-invasive diagnostic reading software that performs post-processing analysis of already acquired CT angiography images.

Are both the FFRangio System and Autoplaque cleared by the FDA?

Yes, both the CathWorks FFRangio System and Autoplaque by Cedars-Sinai AIM are FDA-cleared.